AcelRx Appoints Adrian Adams to Board of Directors as Chairman

        AcelRx Appoints Adrian Adams to Board of Directors as Chairman

PR Newswire

REDWOOD CITY, Calif., Feb. 12, 2013

REDWOOD CITY, Calif., Feb. 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced the appointment of Adrian Adams,
Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc., to
its Board of Directors (Board) as Chairman of the Board. Thomas Schreck,
co-founder of AcelRx and Board member departs from the Board effective
February 11, 2013.

"Adrian Adams is a noted pharma sector executive who has grown and guided a
number of specialty pharmaceutical companies successfully. As our lead
development program, the Sufentanil NanoTab PCA System, transitions from
development toward market, Adrian's leadership, commercial and corporate
perspectives will be invaluable," stated Richard King, President and Chief
Executive Officer of AcelRx. Mr. King added, "We have made great headway over
the past two years, and I thank Tom for his entrepreneurial vision, years of
devoted leadership and commitment to AcelRx as we move to this next stage."

Commenting on his appointment to the AcelRx Board, Mr. Adams said, "It is with
great honor and pleasure that I accept the position of AcelRx's Chairman.
AcelRx has brought its pipeline to an important stage, and Phase 3 NanoTab
System data released to date show great promise for NDA submission. Having
worked with AcelRx CEO Richard King before, I know well his track record and
skills in organizing talent from across clinical, regulatory and marketing to
build brands and look forward to working with my fellow Board members to
deliver value to our stockholders."

Prior to joining Auxilium in late 2011, Mr. Adams served as Chairman and Chief
Executive Officer of Neurologix. Before Neurologix, Mr. Adams served as
President and Chief Executive Officer of Inspire Pharmaceuticals, Inc.,
Sepracor Inc. and Kos Pharmaceuticals, Inc. During his 30 years of
experience, Mr. Adams also held general management and senior marketing
positions at ICI (now part of AstraZeneca), SmithKline Beecham and Novartis.
He has extensive national and international experience and has been
instrumental in launching major global brands in addition to driving
successful corporate development activities encapsulating financing, product
and company acquisitions, in-licensing and company M&A activities. Mr. Adams
graduated from the Royal Institute of Chemistry at Salford University in the
U.K. Mr. Adams recently served as a director of Amylin Pharmaceuticals.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. AcelRx's lead product candidate, the
Sufentanil NanoTab PCA System, which is currently in Phase 3 clinical
development, is designed to solve the problems associated with post-operative
intravenous patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine, the
invasive IV route of delivery and the complexity of infusion pumps. AcelRx has
two additional product candidates which have completed Phase 2 clinical
development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03
for mild sedation, anxiety reduction and pain relief for patients undergoing
painful procedures in a physician's office. AcelRx has initiated a Phase 2
study for a fourth product candidate, ARX-04, a sufentanil formulation for the
treatment of moderate-to-severe acute pain, funded through a grant from U.S.
Army and Medical Research and Materiel Command. For additional information
about AcelRx's clinical programs please visit

Forward Looking Statements
This press release contains forward-looking statements, including, but not
limited to, statements related to the planned or anticipated future clinical
development of AcelRx Pharmaceuticals' product candidates, including the
potential submission of an NDA based on the results of the Phase 3 NanoTab
System trials, and the therapeutic and commercial potential of AcelRx
Pharmaceuticals' product candidates. These forward-looking statements are
based on AcelRx Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals' actual results
and the timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and uncertainties,
which include, without limitation, risks related to: the success, cost and
timing of AcelRx Pharmaceuticals' product development activities and clinical
trials; the uncertain clinical development process; its ability to attract
funding partners or collaborators with development, regulatory and
commercialization expertise; its ability to obtain sufficient financing to
complete development and registration of its product candidates in the United
States and Europe; its ability to obtain and maintain regulatory approvals of
its product candidates; the market potential for its product candidates; the
accuracy of AcelRx Pharmaceuticals' estimates regarding expenses, capital
requirements and needs for financing; and other risks detailed in the "Risk
Factors" and elsewhere inAcelRx Pharmaceuticals'U.S. Securities and Exchange
Commissionfilings and reports, including its Current Report on Form 8-K filed
with theSEConDecember 7, 2012. AcelRx Pharmaceuticals undertakes no duty
or obligation to update any forward-looking statements contained in this
release as a result of new information, future events or changes in its

SOURCE AcelRx Pharmaceuticals, Inc.

Contact: Jim Welch, Chief Financial Officer, +1-650-216-3511,
Press spacebar to pause and continue. Press esc to stop.